Zealand Pharma’s drug for rare metabolic disease smashes phase III

After a year of slumping stock prices, Zealand Pharma is striking back, as its peptide drug improved blood sugar control in infants with the rare disease congenital hyperinsulinemia in a phase III trial. 

In late 2020, the Danish firm Zealand Pharma A/S hit a big obstacle when its peptide drug dasiglucagon failed to treat the rare condition congenital hyperinsulinism (CHI) in a phase III trial. The company’s stock price dropped by 10% in reaction to the news, and only continued downwards the following year as massive volatility struck biotech stocks around the world.

Even the FDA approval of dasiglucagon for the treatment of low blood sugar levels in diabetes in May 2021 failed to reverse Zealand Pharma’s woes. Earlier this year, the company revealed slower sales expectations of the product than it had hoped and made large layoffs in its US operation.

This week, however, things took a positive turn for the firm, as dasiglucagon met the goal of a second phase III trial treating children in hospital with CHI.

The post Zealand Pharma’s drug for rare metabolic disease smashes phase III appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Source

About the Author: Biotech Today

You might like